There are currently no shortages of GLP1s that we are aware of, therefore there is no longer a restriction on starting new patients on GLP1s if they meet the criteria for 3rd line treatment of Type 2 Diabetes Mellitus. If semaglutide (orally as Rybelsus or via injection as Ozempic), dulaglutide (Trulicity) or tirzepatide (Mounjaro) are indicated for a patient then they should be available.
Please follow the Diabetes MCN prescribing guidelines and East Region Formulary link to the Type 2 Diabetes Mellitus guidelines below:
Diabetes MCN Anti-Diabetic Therapy Guidelines for Type 2 Diabetes
